🇺🇸 Platinum-Based Chemotherapy in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malignant Neoplasm Progression — 3 reports (20%)
  2. Death — 2 reports (13.33%)
  3. Drug Ineffective — 2 reports (13.33%)
  4. Nausea — 2 reports (13.33%)
  5. Abscess — 1 report (6.67%)
  6. Alopecia — 1 report (6.67%)
  7. Biliary Obstruction — 1 report (6.67%)
  8. Carbohydrate Antigen 125 Increased — 1 report (6.67%)
  9. Condition Aggravated — 1 report (6.67%)
  10. Decreased Appetite — 1 report (6.67%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Platinum-Based Chemotherapy approved in United States?

Platinum-Based Chemotherapy does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Platinum-Based Chemotherapy in United States?

Genprex, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.